Navigation Links
Cardium Completes $5.3 Million Registered Direct Offering
Date:2/1/2008

rous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that human clinical trials can be conducted and completed in an efficient and successful manner, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that results or trends observed in one clinical study will be reproduced in subsequent studies, that our products or proposed products will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that having a shelf registration statement in place will allow the Company to take advantage of favorable market conditions or that the Company will be effectively able to sell additional common stock on favorable terms. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, and our ability to obtain necessary regulatory approvals and expected qualifications, our limited experience in the development, testing and marketing of therapeutic hypothermia devices and whether our efforts to accelerate the commercialization of such devices and launch new devices will be successful or completed within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and cri
'/>"/>
SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. WuXi PharmaTech Completes Acquisition of AppTec
3. Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
4. Healionics Corporation Completes Series A Financing
5. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
6. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
7. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
8. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
9. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
10. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
11. China Medical Technologies Completes Acquisition of BBE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 According ... Market by Service Type (Consulting, Integration, Deployment & ... by Deployment Model (Public, Private, Others (Hybrid & ... MarketsandMarkets, defines and segments the Cloud Professional Services ... and forecasting of revenues. It also identifies the ...
(Date:10/22/2014)... 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... steps for its Oral Amphotericin B program.  The ... in vitro work involving samples from HIV/AIDS ... to complete pre clinical studies and regulatory filings ... clinical trial, utilizing approximately $700,000 of funding and ...
(Date:10/22/2014)... Research and Markets  has announced the addition of ... Geography - Global Analysis and Forecast (2014 - 2020)" ... electronics, also called as polymer electronics or plastic electronics, ... small conductive molecules and electrically conductive polymers. It is ... carbon based, made using synthetic strategies developed in the ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
Breaking Biology Technology:Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... Aug. 20 GSI Group Inc.,(Nasdaq: GSIG ) ... the tender offer by its indirect wholly-owned subsidiary Eagle,Acquisition ... of,Excel Technology, Inc. (Nasdaq: XLTC ). The initial ... City time, on Tuesday, August 19,2008., The depositary ...
... Strategic Fit with Lilly,s Animal Health Division, GREENFIELD, ... and Company (NYSE: LLY ), today announced that ... to the dairy cow supplement,Posilac(R) (sometribove), as well as ... )., "Global dairy demand is increasing, outstripping supply, ...
... has selected OpenClinica as its electronic data capture (EDC) and ... , ... Ruetlingen, Germany (PRWEB) August ... has selected OpenClinica as its http://www.openclinica.org/section.php?sid=1 [electronic data ...
Cached Biology Technology:GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period 2GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period 3Elanco Announces Acquisition of Posilac(R) Dairy Business 2Elanco Announces Acquisition of Posilac(R) Dairy Business 3OpenClinica EDC Solution Deployed for Retina Implant Studies 2OpenClinica EDC Solution Deployed for Retina Implant Studies 3
(Date:10/16/2014)... 16, 2014) – Post-menopausal women experienced improvements in ... levels or genital bleeding, after 12 weeks of ... fermented soy germ-based nutritional supplement previously shown to ... new peer-reviewed pilot study reported in a poster ... scientific meeting. , "These data documented improved ...
(Date:10/15/2014)... pandemic risk from strains of influenza virus increases with ... to become complacent that the most substantial threats have ... Influenza pandemics arise when a new virus strain – ... – spreads in the human population. There have been ... worst of which – the 1918 Spanish Flu – ...
(Date:10/15/2014)... Ebola virus is spreading rapidly and to an unexpected ... in the past and the virus shows a new ... recorded before. For this reason, the German National Academy ... Science and Engineering, and the Union of the German ... on the Ebola epidemic today. , In the statement ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... SEPTEMBER 9, 2010 The American Society of Agronomy ... Awards Ceremony on Nov. 2 during the scientific society,s ... The annual awards are presented for outstanding contributions to ... , Alan Blaylock, Agrium Advanced Technologies ...
... subset of children with asthma suffers from severe, ... allergic hypersensitivity, according to the results of the ... Research Program (SARP), presented in a recently published ... , a peer-reviewed journal published by Mary Ann ...
... MADISON, WI, September 9, 2010 -- The American Society ... 2010 ASA Fellows at a special Awards Ceremony during ... CA, www.acsmeetings.org . ASA has been selecting ... Society nominate worthy colleagues based on their professional achievements ...
Cached Biology News:American Society of Agronomy announces award recipients 2American Society of Agronomy announces award recipients 3American Society of Agronomy announces award recipients 4Research and insights on severe asthma in children 2American Society of Agronomy presents 2010 Fellows 2American Society of Agronomy presents 2010 Fellows 3American Society of Agronomy presents 2010 Fellows 4American Society of Agronomy presents 2010 Fellows 5American Society of Agronomy presents 2010 Fellows 6
... for RNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. These microarrays ... DNA/RNA Aptamer Microarray Service. Probe ... Microarray contains greater than 1500 known aptamer ...
... Sciences provides a comprehensive service for ... density peptide microarrays synthesized on Paraflo ... recombinant proteins/antibodies or serum samples. This ... sequence designs, binding assays using sample(s) ...
... screening and binding optimization and built on ... synthesis platform. Thousands of customer specified RNA ... Sciences can provide assistance with custom sequence ... of our comprehensive DNA/RNA Aptamer Microarray Service. ...
... commonly used as a fusion partner when ... GSTTag sequence has been reported to enhance ... solubility of its fusion partners. When expressed ... fusion proteins can be purified with immobilized ...
Biology Products: